MRMP

Barnwell Industries, Inc. Reports Results for its Second Quarter and Six Months Ended March 31, 2023 and the Declaration of a Cash Dividend

Retrieved on: 
Monday, May 15, 2023

As there were no sales this quarter, the Company received no percentage of sales payments and no cash distributions in the quarter.

Key Points: 
  • As there were no sales this quarter, the Company received no percentage of sales payments and no cash distributions in the quarter.
  • Capital expenditures incurred for the drilling of these wells and Twining facilities in the six months ended March 31, 2023 totaled approximately $2,236,000.
  • Capitalized costs, including advances to the operator of those wells, totaled $5,354,000 in the six months ended March 31, 2023.
  • The expenses related to this agreement of $501,000 are reflected in the results for the three and six months ended March 31, 2023.

Barnwell Industries, Inc. Reports Earnings for its First Quarter Ended December 31, 2022 and the Declaration of a Cash Dividend

Retrieved on: 
Friday, February 10, 2023

In the three months ended December 31, 2022, Canadian capital expenditures were primarily for the completion and equipping of wells and facilities at Twining and totaled $574,000.

Key Points: 
  • In the three months ended December 31, 2022, Canadian capital expenditures were primarily for the completion and equipping of wells and facilities at Twining and totaled $574,000.
  • The expenses related to this agreement will be reflected in our results for our second quarter ending March 31, 2023.
  • Barnwell ended the quarter with $6,747,000 in working capital, including $6,736,000 in cash and cash equivalents.
  • Forward-looking statements involve risks, uncertainties and assumptions which could cause actual results to differ materially from those contained in such statements.

Barnwell Industries, Inc. Reaches Cooperation and Support Agreement With its Largest Stockholders

Retrieved on: 
Monday, January 23, 2023

The Agreement extends for two years the standstill terms of the previous agreement entered into with the MRMP Stockholders in 2021, ending the potential of a proxy contest at the 2023 annual meeting of stockholders (the “2023 Annual Meeting”).

Key Points: 
  • The Agreement extends for two years the standstill terms of the previous agreement entered into with the MRMP Stockholders in 2021, ending the potential of a proxy contest at the 2023 annual meeting of stockholders (the “2023 Annual Meeting”).
  • The Board has determined that each of Mr. Horowitz and Narbut are independent under applicable NYSE rules and regulations.
  • He has held senior positions at Inverlochy Capital, an asset management firm, and Berggruen Holdings, the family office of Nicolas Berggruen.
  • Forward-looking statements involve risks, uncertainties and assumptions which could cause actual results to differ materially from those contained in such statements.

MRMP Announces Proxy Contest for Full Board Control at Barnwell Industries, Inc.

Retrieved on: 
Thursday, October 27, 2022

MRMP-Managers LLC has announced that it plans to run a proxy contest for full board control at Barnwell Industries, Inc. (NYSE American: BRN) at its 2023 annual meeting of shareholders.

Key Points: 
  • MRMP-Managers LLC has announced that it plans to run a proxy contest for full board control at Barnwell Industries, Inc. (NYSE American: BRN) at its 2023 annual meeting of shareholders.
  • MRMP previously ran a successful proxy contest at Barnwell in 2020, when three of its nominees were elected to the Barnwell board.
  • At that time, MRMP and its related shareholders held approximately 15.4% of the outstanding shares of Barnwell.
  • Today, MRMP and its related shareholders hold approximately 20.1% of the outstanding shares of Barnwell.

MRM Proteomics, Inc. and Agilent Technologies, Inc.: A Collaboration for Progress

Retrieved on: 
Thursday, February 3, 2022

This new partnership will provide a complete solution for quantitative protein and metabolite analysis.

Key Points: 
  • This new partnership will provide a complete solution for quantitative protein and metabolite analysis.
  • Additionally, MRMP commits to hosting regular hands-on and virtual workshops focused on teaching innovative techniques in targeted quantitative proteomics.
  • Training in the operation of the Evosep LC system will be included in these programs.
  • We are impressed with the scanning speed of the Agilent 6495C triple quad MS and the quantitation accuracy that has been repeatedly demonstrated with the MRM Proteomics kits.

MRMP Amends 13D; Sends Follow-Up Letter to Navios Maritime Partners LP

Retrieved on: 
Friday, September 3, 2021

MRMP-Managers LLC (MRMP), announced today that it has sent a follow-up letter to the Board of Directors of Navios Maritime Partners LP (the Company or NMM) (NYSE: NMM) following the announcement by the Company of certain transactions.

Key Points: 
  • MRMP-Managers LLC (MRMP), announced today that it has sent a follow-up letter to the Board of Directors of Navios Maritime Partners LP (the Company or NMM) (NYSE: NMM) following the announcement by the Company of certain transactions.
  • MRMP has attached a copy of its second letter to the Company as an exhibit to the 13D amendment filed today.
  • This press release and MRMPs follow-up letter to NMM (attached as an exhibit to the Schedule 13D/A filed today) contain forward-looking statements.
  • MRMP and its affiliates do not assume any obligation to update any forward-looking statements contained in this press release, except as required by applicable law.